Skip to main content

Table 1 Baseline characteristics of primary Sjögren syndrome (pSS) patients enrolled

From: Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome

Patient Sex Age Disease duration (y, mo) Anti-SS-A Anti-SS-B Biopsy Therapies Manifestations CRP/BSR ESSDAI score
pSS 1 f 50 7mo 181 0.1 Neg Artificial tears Ocular sicca Normal 0
pSS 2 f 43 11y 11mo 240 75 Pos None Ocular, oral and vaginal sicca, glandular swelling Normal 2
pSS 3 f 76 36y 1mo 240 ND ND Artificial saliva Ocular and oral sicca Normal 0
pSS 4 f 48 11y 1mo 240 0.1 ND CFZ-533 *, hydroxychloroquine Ocular and oral sicca ND 17
pSS 5 f 65 Unknown 131 3.2 ND ND ND ND ND
pSS 6 f 50 2y 2mo 240 5 Pos None Ocular sicca Normal 0
pSS 7 m 40 16y 2mo 240 ND Pos Prednisolone p.o. and i.v., artificial tears Ocular and oral sicca haematological manif., vasculitis, glandular swelling, pneumonitis Elevated ESR & Elevated CRP 34
pSS 8 f 60 6mo 240 320 ND None Ocular and oral sicca Elevated CRP 15
pSS 9 f 60 1mo 240 5 Pos Artificial tears Ocular and oral sicca Normal 5
pSS 10 f 30 7mo 5 5 Pos None Ocular and oral sicca Normal 0
pSS 11 m 60 1y 6mo 240 6 Pos None Ocular and oral sicca Normal 1
pSS 12 f 53 3y 1mo 240 320 Pos Methotrexate, hydroxychloroquine, artificial saliva Ocular and oral sicca Normal 6
pSS 13 f 51 9mo 20 ND ND Hydroxychloroquine, artificial tears, artificial saliva Sicca Normal 4
pSS 14 f 64 37y 6mo 240 298 Pos Artificial saliva Ocular and oral sicca Normal 3
pSS 15 f 53 10mo 240 ND Pos Methotrexate, hydroxychloroquine, artificial saliva Ocular, oral and vaginal sicca Normal 8